Event: 4th China BioPharma Convention - Antibody & Vaccine Focus 2014
Dates: October 18 - 20, 2014
Venue: TBD, Shanghai, China
Tel: +86 21 684 07631 ext 8067
Email: rebeccaj@cdmc.org.cn
Biotech drugs have entered the large-scale production stage worldwide. Following the pace, the State Council policy documents have listed the biopharmaceutical as a key development area. It's expected in 2015 that the volume of China's biopharmaceutical market is expected to reach US$100 billion, and antibody drug industry output value will exceed 40 billion. Meanwhile, by the end of 2013, China's vaccine total production is more than CNY 20 billion, and has steadily grown at an average annual rate of 18%. As the strategic products which are critical to the revitalization of national development, vaccine industry development has been paid much emphasis and stimulated by government powerful policies.
As antibody industry has been the most potential subdivision of biopharmaceutical industry and enters the area of blowout, and the soaring speed of vaccine industry, china's biopharma industry will welcome its rapid development period. But with the multinational pharmaceutical companies expanding scale, stronger strength, speeding up to generic drugs, and more intense competition of the market, China's pharmaceutical industry will face a severe challenge.
In order to solve the worldwide competition in biopharma industry and promote the innovation as well as power the R&D and industrialization of China's biopharma industry, CDMC Events has gathered the key players and frontier associations to jointly hold the 4th China BioPharma Convention-Antibody & Vaccine Focus from October 18-20 2014 in Shanghai, China. The event will gather the industry leaders worldwide to discuss and explore the hot issues across market policy, R&D of new drugs, projects docking, clinical trials in the world, especially in China to lead the trend of the new technology.